Multiple Myeloma (Kahler Disease) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Multiple Myeloma (Kahler Disease) – Pipeline Review, H2 2017’, provides an overview of the Multiple Myeloma (Kahler Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease)

The report reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Multiple Myeloma (Kahler Disease) therapeutics and enlists all their major and minor projects

The report assesses Multiple Myeloma (Kahler Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler Disease)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

Acceleron Pharma Inc

Actinium Pharmaceuticals Inc

Active Biotech AB

Aduro BioTech Inc

Aeglea BioTherapeutics Inc

Affimed GmbH

AIMM Therapeutics BV

Alissa Pharma

Altor BioScience Corp

Amgen Inc

Anthera Pharmaceuticals Inc

APIM Therapeutics AS

Arno Therapeutics Inc

Array BioPharma Inc

Asana BioSciences LLC

Aslan Pharmaceuticals Pte Ltd

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Aurigene Discovery Technologies Ltd

Autolus Ltd

Bayer AG

Bellicum Pharmaceuticals Inc

BeyondSpring Pharmaceuticals Inc

Biomunex Pharmaceuticals

Biotest AG

bluebird bio Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Calithera Biosciences Inc

CanBas Co Ltd

Celgene Corp

Cell Source Inc

Cellectar Biosciences Inc

Cellectis SA

Cellerant Therapeutics Inc

Celleron Therapeutics Ltd

CellProtect Nordic Pharmaceuticals AB

Cellular Biomedicine Group Inc

Celyad SA

Chong Kun Dang Pharmaceutical Corp

Chugai Pharmaceutical Co Ltd

Curis Inc

Cyclacel Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

DC Prime BV

Eli Lilly and Co

Enceladus Pharmaceuticals BV

eTheRNA Immunotherapies NV

Exelixis Inc

F. Hoffmann-La Roche Ltd

Five Prime Therapeutics Inc

Galileo Research srl

Gamida Cell Ltd

Genenta Science srl

Genentech Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Gliknik Inc

GlycoMimetics Inc

GP Pharm SA

GT Biopharma Inc

Heidelberg Pharma GmbH

HitGen LTD

IGF Oncology LLC

ImmunGene Inc

Immunomedics Inc

Incyte Corp

Inflection Biosciences Ltd

Inventiva

Istesso Ltd

Janpix Inc

Jasco Pharmaceuticals LLC

Johnson & Johnson

Juno Therapeutics Inc

JW Pharmaceutical Corp

Kancera AB

Karus Therapeutics Ltd

Karyopharm Therapeutics Inc

Kite Pharma Inc

Klyss Biotech Inc

Leadiant Biosciences Inc

Les Laboratoires Servier SAS

Madrigal Pharmaceuticals Inc.

MediGene AG

MedImmune LLC

Merck & Co Inc

Midatech Pharma US Inc

Millennium Pharmaceuticals Inc

MimiVax LLC

Molecular Partners AG

Molecular Templates Inc

MolMed SpA

MorphoSys AG

NantKwest Inc

NBE-Therapeutics AG

Neonc Technologies Inc

Nippon Kayaku Co Ltd

Nordic Nanovector ASA

Novartis AG

Noxxon Pharma AG

Oncodesign SA

Oncolytics Biotech Inc

Onconova Therapeutics Inc

Oncopeptides AB

OncoTartis Inc

Ono Pharmaceutical Co Ltd

Peptinov SAS

Pfizer Inc

Pharma Mar SA

Phosplatin Therapeutics LLC

Polyphor Ltd

Prescient Therapeutics Ltd

Progenra Inc

RedHill Biopharma Ltd

Regeneron Pharmaceuticals Inc

Rhizen Pharmaceuticals SA

Samyang Biopharmaceuticals Corp

Sanofi

Seattle Genetics Inc

Sellas Life Sciences Group Ltd

Selvita SA

Senhwa Biosciences Inc

Shuttle Pharmaceuticals LLC

Sorrento Therapeutics Inc

Spectrum Pharmaceuticals Inc

Stemline Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Surface Oncology Inc

Sutro Biopharma Inc

Taiho Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd

Targazyme Inc

TeneoBio Inc

Terpenoid Therapeutics Inc

Tiziana Life Sciences Plc

TRACON Pharmaceuticals Inc

Tragara Pharmaceuticals Inc

Transgene Biotek Ltd

Trillium Therapeutics Inc

TTY Biopharm Company Ltd

Unum Therapeutics Inc

Vaccibody AS

Vaxil Bio Therapeutics Ltd

Vivolux AB

Vyriad Inc

XTL Biopharmaceuticals Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Multiple Myeloma (Kahler Disease) - Overview 9

Multiple Myeloma (Kahler Disease) - Therapeutics Development 10

Multiple Myeloma (Kahler Disease) - Therapeutics Assessment 55

Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development 81

Multiple Myeloma (Kahler Disease) - Drug Profiles 154

Multiple Myeloma (Kahler Disease) - Dormant Projects 1161

Multiple Myeloma (Kahler Disease) - Discontinued Products 1177

Multiple Myeloma (Kahler Disease) - Product Development Milestones 1180

Appendix 1189

List of Tables

List of Tables

Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2017 46

Number of Products under Development by Companies, H2 2017 48

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 49

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 50

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 51

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 52

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 53

Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 54

Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 55

Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017 56

Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017 57

Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017 58

Number of Products under Development by Universities/Institutes, H2 2017 59

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 61

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 62

Products under Development by Companies, H2 2017 63

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 64

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 65

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 66

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 67

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 68

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 69

Products under Development by Companies, H2 2017 (Contd..7), H2 2017 70

Products under Development by Companies, H2 2017 (Contd..8), H2 2017 71

Products under Development by Companies, H2 2017 (Contd..9), H2 2017 72

Products under Development by Companies, H2 2017 (Contd..10), H2 2017 73

Products under Development by Companies, H2 2017 (Contd..11), H2 2017 74

Products under Development by Companies, H2 2017 (Contd..12), H2 2017 75

Products under Development by Companies, H2 2017 (Contd..13), H2 2017 76

Products under Development by Companies, H2 2017 (Contd..14), H2 2017 77

Products under Development by Companies, H2 2017 (Contd..15), H2 2017 78

Products under Development by Companies, H2 2017 (Contd..16), H2 2017 79

Products under Development by Companies, H2 2017 (Contd..17), H2 2017 80

Products under Development by Companies, H2 2017 (Contd..18), H2 2017 81

Products under Development by Companies, H2 2017 (Contd..19), H2 2017 82

Products under Development by Companies, H2 2017 (Contd..20), H2 2017 83

Products under Development by Companies, H2 2017 (Contd..21), H2 2017 84

Products under Development by Companies, H2 2017 (Contd..22), H2 2017 85

Products under Development by Companies, H2 2017 (Contd..23), H2 2017 86

Products under Development by Universities/Institutes, H2 2017 87

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 88

Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 89

Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017 90

Number of Products by Stage and Target, H2 2017 92

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 93

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 94

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 95

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 96

Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017 97

Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017 98

Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017 99

Number of Products by Stage and Target, H2 2017 (Contd..8), H2 2017 100

Number of Products by Stage and Target, H2 2017 (Contd..9), H2 2017 101

Number of Products by Stage and Mechanism of Action, H2 2017 103

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 104

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 105

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 106

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 107

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017 108

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017 109

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017 110

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..8), H2 2017 111

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..9), H2 2017 112

Number of Products by Stage and Route of Administration, H2 2017 114

Number of Products by Stage and Molecule Type, H2 2017 116

Multiple Myeloma (Kahler Disease) – Pipeline by 4SC AG, H2 2017 117

Multiple Myeloma (Kahler Disease) – Pipeline by AbbVie Inc, H2 2017 118

Multiple Myeloma (Kahler Disease) – Pipeline by Acceleron Pharma Inc, H2 2017 118

Multiple Myeloma (Kahler Disease) – Pipeline by Actinium Pharmaceuticals Inc, H2 2017 119

Multiple Myeloma (Kahler Disease) – Pipeline by Active Biotech AB, H2 2017 119

Multiple Myeloma (Kahler Disease) – Pipeline by Aduro BioTech Inc, H2 2017 120

Multiple Myeloma (Kahler Disease) – Pipeline by Aeglea BioTherapeutics Inc, H2 2017 120

Multiple Myeloma (Kahler Disease) – Pipeline by Affimed GmbH, H2 2017 121

Multiple Myeloma (Kahler Disease) – Pipeline by AIMM Therapeutics BV, H2 2017 121

Multiple Myeloma (Kahler Disease) – Pipeline by Alissa Pharma, H2 2017 121

Multiple Myeloma (Kahler Disease) – Pipeline by Altor BioScience Corp, H2 2017 122

Multiple Myeloma (Kahler Disease) – Pipeline by Amgen Inc, H2 2017 123

Multiple Myeloma (Kahler Disease) – Pipeline by Anthera Pharmaceuticals Inc, H2 2017 123

Multiple Myeloma (Kahler Disease) – Pipeline by APIM Therapeutics AS, H2 2017 124

Multiple Myeloma (Kahler Disease) – Pipeline by Arno Therapeutics Inc, H2 2017 124

Multiple Myeloma (Kahler Disease) – Pipeline by Array BioPharma Inc, H2 2017 125

Multiple Myeloma (Kahler Disease) – Pipeline by Asana BioSciences LLC, H2 2017 125

Multiple Myeloma (Kahler Disease) – Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017 125

Multiple Myeloma (Kahler Disease) – Pipeline by Astellas Pharma Inc, H2 2017 126

Multiple Myeloma (Kahler Disease) – Pipeline by Astex Pharmaceuticals Inc, H2 2017 126

Multiple Myeloma (Kahler Disease) – Pipeline by AstraZeneca Plc, H2 2017 127

Multiple Myeloma (Kahler Disease) – Pipeline by Atara Biotherapeutics Inc, H2 2017 127

Multiple Myeloma (Kahler Disease) – Pipeline by Aurigene Discovery Technologies Ltd, H2 2017 128

Multiple Myeloma (Kahler Disease) – Pipeline by Autolus Ltd, H2 2017 128

Multiple Myeloma (Kahler Disease) – Pipeline by Bayer AG, H2 2017 129

Multiple Myeloma (Kahler Disease) – Pipeline by Bellicum Pharmaceuticals Inc, H2 2017 129

Multiple Myeloma (Kahler Disease) – Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017 130

Multiple Myeloma (Kahler Disease) – Pipeline by Biomunex Pharmaceuticals, H2 2017 130

Multiple Myeloma (Kahler Disease) – Pipeline by Biotest AG, H2 2017 131

Multiple Myeloma (Kahler Disease) – Pipeline by bluebird bio Inc, H2 2017 131

Multiple Myeloma (Kahler Disease) – Pipeline by Boehringer Ingelheim GmbH, H2 2017 132

Multiple Myeloma (Kahler Disease) – Pipeline by Boston Biomedical Inc, H2 2017 132

Multiple Myeloma (Kahler Disease) – Pipeline by Bristol-Myers Squibb Co, H2 2017 133

Multiple Myeloma (Kahler Disease) – Pipeline by Calithera Biosciences Inc, H2 2017 133

Multiple Myeloma (Kahler Disease) – Pipeline by CanBas Co Ltd, H2 2017 134

Multiple Myeloma (Kahler Disease) – Pipeline by Celgene Corp, H2 2017 135

Multiple Myeloma (Kahler Disease) – Pipeline by Cell Source Inc, H2 2017 135

Multiple Myeloma (Kahler Disease) – Pipeline by Cellectar Biosciences Inc, H2 2017 136

Multiple Myeloma (Kahler Disease) – Pipeline by Cellectis SA, H2 2017 136

Multiple Myeloma (Kahler Disease) – Pipeline by Cellerant Therapeutics Inc, H2 2017 137

Multiple Myeloma (Kahler Disease) – Pipeline by Celleron Therapeutics Ltd, H2 2017 137

Multiple Myeloma (Kahler Disease) – Pipeline by CellProtect Nordic Pharmaceuticals AB, H2 2017 138

Multiple Myeloma (Kahler Disease) – Pipeline by Cellular Biomedicine Group Inc, H2 2017 138

Multiple Myeloma (Kahler Disease) – Pipeline by Celyad SA, H2 2017 139

Multiple Myeloma (Kahler Disease) – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017 139

Multiple Myeloma (Kahler Disease) – Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017 140

Multiple Myeloma (Kahler Disease) – Pipeline by Curis Inc, H2 2017 140

Multiple Myeloma (Kahler Disease) – Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017 141

Multiple Myeloma (Kahler Disease) – Pipeline by Daiichi Sankyo Co Ltd, H2 2017 141

Multiple Myeloma (Kahler Disease) – Pipeline by DC Prime BV, H2 2017 142

Multiple Myeloma (Kahler Disease) – Pipeline by Eli Lilly and Co, H2 2017 142

Multiple Myeloma (Kahler Disease) – Pipeline by Enceladus Pharmaceuticals BV, H2 2017 142

Multiple Myeloma (Kahler Disease) – Pipeline by eTheRNA Immunotherapies NV, H2 2017 143

Multiple Myeloma (Kahler Disease) – Pipeline by Exelixis Inc, H2 2017 143

Multiple Myeloma (Kahler Disease) – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 144

Multiple Myeloma (Kahler Disease) – Pipeline by Five Prime Therapeutics Inc, H2 2017 144

Multiple Myeloma (Kahler Disease) – Pipeline by Galileo Research srl, H2 2017 145

Multiple Myeloma (Kahler Disease) – Pipeline by Gamida Cell Ltd, H2 2017 145

Multiple Myeloma (Kahler Disease) – Pipeline by Genenta Science srl, H2 2017 146

Multiple Myeloma (Kahler Disease) – Pipeline by Genentech Inc, H2 2017 146

Multiple Myeloma (Kahler Disease) – Pipeline by GlaxoSmithKline Plc, H2 2017 147

Multiple Myeloma (Kahler Disease) – Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017 147

Multiple Myeloma (Kahler Disease) – Pipeline by Gliknik Inc, H2 2017 148

Multiple Myeloma (Kahler Disease) – Pipeline by GlycoMimetics Inc, H2 2017 148

Multiple Myeloma (Kahler Disease) – Pipeline by GP Pharm SA, H2 2017 148

Multiple Myeloma (Kahler Disease) – Pipeline by GT Biopharma Inc, H2 2017 149

Multiple Myeloma (Kahler Disease) – Pipeline by Heidelberg Pharma GmbH, H2 2017 149

Multiple Myeloma (Kahler Disease) – Pipeline by HitGen LTD, H2 2017 150

Multiple Myeloma (Kahler Disease) – Pipeline by IGF Oncology LLC, H2 2017 150

Multiple Myeloma (Kahler Disease) – Pipeline by ImmunGene Inc, H2 2017 150

Multiple Myeloma (Kahler Disease) – Pipeline by Immunomedics Inc, H2 2017 151

Multiple Myeloma (Kahler Disease) – Pipeline by Incyte Corp, H2 2017 152

Multiple Myeloma (Kahler Disease) – Pipeline by Inflection Biosciences Ltd, H2 2017 152

Multiple Myeloma (Kahler Disease) – Pipeline by Inventiva, H2 2017 153

Multiple Myeloma (Kahler Disease) – Pipeline by Istesso Ltd, H2 2017 153

Multiple Myeloma (Kahler Disease) – Pipeline by Janpix Inc, H2 2017 153

Multiple Myeloma (Kahler Disease) – Pipeline by Jasco Pharmaceuticals LLC, H2 2017 154

Multiple Myeloma (Kahler Disease) – Pipeline by Johnson & Johnson, H2 2017 155

Multiple Myeloma (Kahler Disease) – Pipeline by Juno Therapeutics Inc, H2 2017 155

Multiple Myeloma (Kahler Disease) – Pipeline by JW Pharmaceutical Corp, H2 2017 156

Multiple Myeloma (Kahler Disease) – Pipeline by Kancera AB, H2 2017 156

Multiple Myeloma (Kahler Disease) – Pipeline by Karus Therapeutics Ltd, H2 2017 157

Multiple Myeloma (Kahler Disease) – Pipeline by Karyopharm Therapeutics Inc, H2 2017 157

Multiple Myeloma (Kahler Disease) – Pipeline by Kite Pharma Inc, H2 2017 158

Multiple Myeloma (Kahler Disease) – Pipeline by Klyss Biotech Inc, H2 2017 158

Multiple Myeloma (Kahler Disease) – Pipeline by Leadiant Biosciences Inc, H2 2017 159

Multiple Myeloma (Kahler Disease) – Pipeline by Les Laboratoires Servier SAS, H2 2017 159

Multiple Myeloma (Kahler Disease) – Pipeline by Madrigal Pharmaceuticals Inc., H2 2017 159

Multiple Myeloma (Kahler Disease) – Pipeline by MediGene AG, H2 2017 160

Multiple Myeloma (Kahler Disease) – Pipeline by MedImmune LLC, H2 2017 160

Multiple Myeloma (Kahler Disease) – Pipeline by Merck & Co Inc, H2 2017 161

Multiple Myeloma (Kahler Disease) – Pipeline by Midatech Pharma US Inc, H2 2017 161

Multiple Myeloma (Kahler Disease) – Pipeline by Millennium Pharmaceuticals Inc, H2 2017 162

Multiple Myeloma (Kahler Disease) – Pipeline by MimiVax LLC, H2 2017 162

Multiple Myeloma (Kahler Disease) – Pipeline by Molecular Partners AG, H2 2017 163

Multiple Myeloma (Kahler Disease) – Pipeline by Molecular Templates Inc, H2 2017 163

Multiple Myeloma (Kahler Disease) – Pipeline by MolMed SpA, H2 2017 164

Multiple Myeloma (Kahler Disease) – Pipeline by MorphoSys AG, H2 2017 164

Multiple Myeloma (Kahler Disease) – Pipeline by NantKwest Inc, H2 2017 165

Multiple Myeloma (Kahler Disease) – Pipeline by NBE-Therapeutics AG, H2 2017 165

Multiple Myeloma (Kahler Disease) – Pipeline by Neonc Technologies Inc, H2 2017 165

Multiple Myeloma (Kahler Disease) – Pipeline by Nippon Kayaku Co Ltd, H2 2017 166

Multiple Myeloma (Kahler Disease) – Pipeline by Nordic Nanovector ASA, H2 2017 166

Multiple Myeloma (Kahler Disease) – Pipeline by Novartis AG, H2 2017 167

Multiple Myeloma (Kahler Disease) – Pipeline by Noxxon Pharma AG, H2 2017 168

Multiple Myeloma (Kahler Disease) – Pipeline by Oncodesign SA, H2 2017 168

Multiple Myeloma (Kahler Disease) – Pipeline by Oncolytics Biotech Inc, H2 2017 169

Multiple Myeloma (Kahler Disease) – Pipeline by Onconova Therapeutics Inc, H2 2017 169

Multiple Myeloma (Kahler Disease) – Pipeline by Oncopeptides AB, H2 2017 170

Multiple Myeloma (Kahler Disease) – Pipeline by OncoTartis Inc, H2 2017 170

Multiple Myeloma (Kahler Disease) – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 171

Multiple Myeloma (Kahler Disease) – Pipeline by Peptinov SAS, H2 2017 171

Multiple Myeloma (Kahler Disease) – Pipeline by Pfizer Inc, H2 2017 172

Multiple Myeloma (Kahler Disease) – Pipeline by Pharma Mar SA, H2 2017 172

Multiple Myeloma (Kahler Disease) – Pipeline by Phosplatin Therapeutics LLC, H2 2017 173

Multiple Myeloma (Kahler Disease) – Pipeline by Polyphor Ltd, H2 2017 173

Multiple Myeloma (Kahler Disease) – Pipeline by Prescient Therapeutics Ltd, H2 2017 173

Multiple Myeloma (Kahler Disease) – Pipeline by Progenra Inc, H2 2017 174

Multiple Myeloma (Kahler Disease) – Pipeline by RedHill Biopharma Ltd, H2 2017 174

Multiple Myeloma (Kahler Disease) – Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 175

Multiple Myeloma (Kahler Disease) – Pipeline by Rhizen Pharmaceuticals SA, H2 2017 175

Multiple Myeloma (Kahler Disease) – Pipeline by Samyang Biopharmaceuticals Corp, H2 2017 176

Multiple Myeloma (Kahler Disease) – Pipeline by Sanofi, H2 2017 176

Multiple Myeloma (Kahler Disease) – Pipeline by Seattle Genetics Inc, H2 2017 177

Multiple Myeloma (Kahler Disease) – Pipeline by Sellas Life Sciences Group Ltd, H2 2017 177

Multiple Myeloma (Kahler Disease) – Pipeline by Selvita SA, H2 2017 178

Multiple Myeloma (Kahler Disease) – Pipeline by Senhwa Biosciences Inc, H2 2017 178

Multiple Myeloma (Kahler Disease) – Pipeline by Shuttle Pharmaceuticals LLC, H2 2017 178

Multiple Myeloma (Kahler Disease) – Pipeline by Sorrento Therapeutics Inc, H2 2017 179

Multiple Myeloma (Kahler Disease) – Pipeline by Spectrum Pharmaceuticals Inc, H2 2017 180

Multiple Myeloma (Kahler Disease) – Pipeline by Stemline Therapeutics Inc, H2 2017 180

Multiple Myeloma (Kahler Disease) – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017 181

Multiple Myeloma (Kahler Disease) – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 181

Multiple Myeloma (Kahler Disease) – Pipeline by Surface Oncology Inc, H2 2017 181

Multiple Myeloma (Kahler Disease) – Pipeline by Sutro Biopharma Inc, H2 2017 182

Multiple Myeloma (Kahler Disease) – Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017 182

Multiple Myeloma (Kahler Disease) – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 183

Multiple Myeloma (Kahler Disease) – Pipeline by Targazyme Inc, H2 2017 183

Multiple Myeloma (Kahler Disease) – Pipeline by TeneoBio Inc, H2 2017 184

Multiple Myeloma (Kahler Disease) – Pipeline by Terpenoid Therapeutics Inc, H2 2017 184

Multiple Myeloma (Kahler Disease) – Pipeline by Tiziana Life Sciences Plc, H2 2017 184

Multiple Myeloma (Kahler Disease) – Pipeline by TRACON Pharmaceuticals Inc, H2 2017 185

Multiple Myeloma (Kahler Disease) – Pipeline by Tragara Pharmaceuticals Inc, H2 2017 185

Multiple Myeloma (Kahler Disease) – Pipeline by Transgene Biotek Ltd, H2 2017 186

Multiple Myeloma (Kahler Disease) – Pipeline by Trillium Therapeutics Inc, H2 2017 186

Multiple Myeloma (Kahler Disease) – Pipeline by TTY Biopharm Company Ltd, H2 2017 187

Multiple Myeloma (Kahler Disease) – Pipeline by Unum Therapeutics Inc, H2 2017 187

Multiple Myeloma (Kahler Disease) – Pipeline by Vaccibody AS, H2 2017 187

Multiple Myeloma (Kahler Disease) – Pipeline by Vaxil Bio Therapeutics Ltd, H2 2017 188

Multiple Myeloma (Kahler Disease) – Pipeline by Vivolux AB, H2 2017 188

Multiple Myeloma (Kahler Disease) – Pipeline by Vyriad Inc, H2 2017 189

Multiple Myeloma (Kahler Disease) – Pipeline by XTL Biopharmaceuticals Ltd, H2 2017 189

Multiple Myeloma (Kahler Disease) – Dormant Projects, H2 2017 1197

Multiple Myeloma (Kahler Disease) – Dormant Projects, H2 2017 (Contd..1), H2 2017 1198

Multiple Myeloma (Kahler Disease) – Dormant Projects, H2 2017 (Contd..2), H2 2017 1199

Multiple Myeloma (Kahler Disease) – Dormant Projects, H2 2017 (Contd..3), H2 2017 1200

Multiple Myeloma (Kahler Disease) – Dormant Projects, H2 2017 (Contd..4), H2 2017 1201

Multiple Myeloma (Kahler Disease) – Dormant Projects, H2 2017 (Contd..5), H2 2017 1202

Multiple Myeloma (Kahler Disease) – Dormant Projects, H2 2017 (Contd..6), H2 2017 1203

Multiple Myeloma (Kahler Disease) – Dormant Projects, H2 2017 (Contd..7), H2 2017 1204

Multiple Myeloma (Kahler Disease) – Dormant Projects, H2 2017 (Contd..8), H2 2017 1205

Multiple Myeloma (Kahler Disease) – Dormant Projects, H2 2017 (Contd..9), H2 2017 1206

Multiple Myeloma (Kahler Disease) – Dormant Projects, H2 2017 (Contd..10), H2 2017 1207

Multiple Myeloma (Kahler Disease) – Dormant Projects, H2 2017 (Contd..11), H2 2017 1208

Multiple Myeloma (Kahler Disease) – Dormant Projects, H2 2017 (Contd..12), H2 2017 1209

Multiple Myeloma (Kahler Disease) – Dormant Projects, H2 2017 (Contd..13), H2 2017 1210

Multiple Myeloma (Kahler Disease) – Dormant Projects, H2 2017 (Contd..14), H2 2017 1211

Multiple Myeloma (Kahler Disease) – Dormant Projects, H2 2017 (Contd..15), H2 2017 1212

Multiple Myeloma (Kahler Disease) – Discontinued Products, H2 2017 1213

Multiple Myeloma (Kahler Disease) – Discontinued Products, H2 2017 (Contd..1), H2 2017 1214

Multiple Myeloma (Kahler Disease) – Discontinued Products, H2 2017 (Contd..2), H2 2017 1215

List of Figures

List of Figures

Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2017 46

Number of Products under Development by Companies, H2 2017 47

Number of Products under Development by Universities/Institutes, H2 2017 59

Number of Products by Top 10 Targets, H2 2017 91

Number of Products by Stage and Top 10 Targets, H2 2017 91

Number of Products by Top 10 Mechanism of Actions, H2 2017 102

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 102

Number of Products by Routes of Administration, H2 2017 113

Number of Products by Stage and Routes of Administration, H2 2017 113

Number of Products by Top 10 Molecule Types, H2 2017 115

Number of Products by Stage and Top 10 Molecule Types, H2 2017 115

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports